expect high focu continu perform
revers idiosyncrat disloc
paclitaxel risk
rise tide sink boat sector ytd perform rel line
 devic vs
nearli perform healthcar consist outlook
improv organ growth fundament fund flow devic
underpin rational out-performance clearli greater valuat
pushback level larg cap devic trade price-to-earnings premium vs
 compar premium month ago concern drug
suppli chain continu buoy interest devic tool rel
healthcar sub-sector amid out-performance three trend stick
larg cap underperform outperform year new investor
interest center value-ori stori baxter see upgrad
zimmer march evidenc materi disloc multipl smid cap
paclitaxel expos stock question impact posit
model impli bp comp adjust deceler
util environ appear stabl see hospit survey suggest
growth stabil achiev mani name alreadi reflect
share opportun lie controversi focu
paclitaxel print risk well understood see paclitaxel risk like
impact use materi consensu number may low enough
bd clearli expos financi
sentiment perspect see paclitaxel get price
take risk-adjust approach number guidanc given lack
visibl dcb adcom june see risk guidanc
head ep broad fundament solid see ceo seri
recap updat dcb assumpt modest chang fx drive
underli revenu growth rate ep
compani guidanc rang
boston scientif boston estim eluvia could deliv
bp growth less like materi
believ guidanc rang risk continu pocket
upsid model notabl structur heart lotu launch
march europ expect approv us exalt
like revenu contributor import catalyst boston enter
flexibl duodenoscop market lower
estim reflect eluvia urolog suppli
return rel current stock price
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
disrupt remain comfort middl
detail view closer
quarter two dynam focu ep guidanc
see risk-adjust given recent refinanc see inch back
revenu outlook compani face tougher
comp limit pipelin driver earli year like need
make conserv assumpt dcb similar bd
would expect conserv outlook top-line near
debat guidanc guid
quarter investor look see whether guidanc bracket
abiom under-perform post stemi reflect growth concern
anniversari key catalyst coupl subdu
catalyst pathway concern upcom reimburs fda
warn letter rp recent risk-adjust number
see recent concern reflect expect guidanc
bracket street high end
haemonet pt out-performance last year lag
coverag pt ytd expect larg fraction adopt
subsequ earn expect got ahead stock momentum
street consensu approach reason level remain
top bottom line see plasma guidanc
ep reason rang guidanc approxim
consensu offer relief sustain out-performance tie
visibl larg nexsi contract
volatil continu smid cap resurg histor risk
irhythm manag chang drove materi stock
action march creat setup disconnect versu underli
expect materi upsid estim model pt
momentum deceler competit fear keep mani sidelin
print think battl two dynam
drive volatil next month libr approv come ahead
quarter like present near-term buy opportun abbott
commentari libr pipelin next week focu
irhythm expect upsid quarter instil confid
commerci ramp limit impact competit anticip
relief quarter recoveri may mute reimburs risk
better contain commentari call upcom hr
analyst day may address reimburs opportun
activism-driven manag chang push share
suggest expect risen fast would note
valuat sit sale compani lag
smid pt sinc high achiev year ago guidanc
origin perceiv conserv recent suspens
usher concern like weakest print year given prior
commerci disrupt new platform contribut
convinc debat alter see weak buy
opportun upgrad thesi center better execut
platform pipelin stori investor attent shift
forward quarter matter less
high expect met zimmer out-performance hill-rom
perceiv conserv guidanc set high bar think compani
deliv investor expect
zimmer biomet enthusiasm follow aao see
out-performance pt vs coverag recent manag
commentari led heighten expect quarter
howev consensu estim organ growth pt
momentum deceler leav room zimmer biomet post four
consecut quarter momentum improv stabil
would drive high end manag object first
time compani deliv growth year continu
acceler enough drive momentum stock
pipelin contribut
hill-rom hold hill-rom guidanc core growth impli pt
momentum deceler annual guidanc also suggest pt
momentum acceler view conserv given
recent intern momentum strength base busi
comp pipelin revenu like ahead schedul expect
upsid estim note hill-rom deliv core growth last
quarter vs guid hill-rom beat guidanc may move higher
would second consecut beat guidanc maintain
medic devic coverag under-perform
bp health under-perform coverag pt coverag
outperform provid servic pharma
within coverag ortho perform strongest follow
equip suppli cardio
med-tech sector
med-tech capit
ntm price-to-earnings rel
ntm price-to-earnings rel
exhibit cardio ntm price-to-earnings rel
exhibit ortho ntm price-to-earnings rel
exhibit suppli ntm price-to-earnings rel
exhibit organ growth med-tech segment
exhibit year stack organ growth med-tech segment
exhibit organ growth capit
exhibit yr stack organ growth capit
exhibit ms med-tech coverag base case return rel
current stock price
return rel current stock price
million except ep
path organ drive upsid guidanc
better expect given ytd
perform expect set closer higher end
rang mse estim impli bp
momentum deceler note impli momentum
stabil model assum bp deceler
diagnost part driven aler anniversari strong flu
season last year back aler model suggest
bp deceler may materi stabil
diagnost impli addit bp growth epd
model bp deceler driven part product
winddown account deceler
comfort cardio neuromod growth rate
repres bp momentum acceler
includ upsid heartmat share gain mitraclip
acceler discuss expect fx line
manag guidanc headwind remain
comfort high end earn rang
remain comfort upper half
earn rang organ guidanc
rang
expect libr key focu call diabet
model growth us pt momentum acceler
growth ex us repres stabil libr ad
patient last quarter instal base grew patient support
momentum acceler remain comfort estim expect
libr signific focu call continu expect approv via
icgm channel manag commentari like continu suggest approv
fda approv recent diabet devic ahead expect prior
two year expect updat payer momentum pharmaci continu
discuss tier
mitraclip acceler ahead ncd mitraclip deliv growth
driven acceler us market model assum
growth continu contribut bp corpor growth may prove
conserv mitraclip momentum continu acceler follow robust coapt
data present tct see coapt game continu expect mitraclip
growth acceler dilig suggest immedi impact
referr channel pascal trial closur cap post fda approv
last month see may temper expect backhalf see ncd
approv continu expect ncd approv end year preliminari
injunct date mitraclip-pasc litig next catalyst april
see
result announc april pre-market confer call et
million except ep
expect appropri guidanc assum
abiom set guidanc bracket street
high end street mid-point
modestli lower outlook
like evid modest deceler us partial off-set
ramp japanes commerci roll-out us growth may slow
given anniversari acut benefit pma
expans see tct call arm see possibl
rp headwind see model us growth ex us
becom bigger driver model growth
japan roll-out upcom reimburs
decis franc could drive upsid number manag
commentari suggest japan sale would
optimist japan continu outpac expect
busi pace deliv vs origin guidanc
manag remain conserv
commentari continu see possibl japan
remain toward higher end path sale
may optimist guidanc come expect
rang manag note past timelin
may slip quarter ltm basi model impli
sale
rp pci growth focu item quarter lower rp estim
light fda warn letter model y/i growth
versu street bp momentum deceler bp
deceler highlight rp pci growth two focu area
dilig suggest could lower util rp post fda warn
letter see us rp sale total corpor sale rp
contribut bp growth bear case rp sale declin
impli bp headwind us growth lower rp
estim manag commentari call
suggest new data shown rp mortal post-approv studi
line seen pre-approv studi proper patient
identif broader protocol drive rp growth time therefor
rp disrupt fade
pci patient growth saw signific momentum deceler pt
caus concern manag suggest quarterli
dynam structur chang busi may justifi given
pt momentum acceler pci patient growth seen note
month period momentum pt pci model assum pt
pci pt shock patient deceler ex us model stabil europ
germani recov sale japan may
assess ipp reimburs concern april ipp draft final rule calcul
volatil last two year
weight averag basi shock pci code consolid see
final rate revis posit
code matur volatil ebb code rel
new prior year movement rais concern initi propos rate
expect mid april impella bring cost hospit charg declin ceo
mike minogu suggest reimburs could come over-tim hard call
draft propos fall movement possibl said final
rule like modifi sure modest cut would meaning affect
util given still impli headroom pci/shock procedur
like recent stock weak pt under-perform vs coverag ytd
least partial account reimburs concern continu expect
million except ep
street cautiou low mark
growth earn number reason sale
model flat growth given chronic distribut flu
comp on-q suppli headwind could somewhat
off-set eas comp leiter ramp later year
limit benefit coolief direct-to-consum
campaign earn pressur heavier
invest growth relat coolief
limit benefit cost save build throughout
year limit sale growth street appear
adequ account top-lin headwind may
conserv oper margin vs mse ep
vs mse
comfort sale cautiou annual guidanc
avano guid revenu growth includ
organ sale back pt impact game readi
guidanc lower end avano state mid-singl digit
profil given delay inventori destock chronic
continu headwind within on-q busi normal flu season
comfort consensu sale flat organ growth
concern recoveri on-q busi may take longer given intra-quart
news suppli shortag current model assum low-singl digit on-q
driven upper singl digit growth recoveri worth bp
corpor growth without challeng avano reach upper
end guidanc
unlik debat alter commentari monitor number
on-q recoveri believ visibl recoveri limit suppli continu
problem even leiter continu ramp
coolief growth manag like remain bullish prospect
coolief given recent data see direct-to-consum market even
enter space ampl runway given larg market
potenti improv reimburs
transform larg go invest year avano
discuss ep call margin pressur
expect compani view cost transform shift
 acquisit remain key focu manag near-term expect
deal remain rel small focu near-adjac potenti
larger deal cost transform plan along
expect modest upsid quarter baxter guid
organ growth reflect pt momentum
deceler base foreseen headwind includ
y/i declin brevi sale bp ii heighten iv solut
order impact bp iii in-cent hd
contract exit impact bp notwithstand
pt growth headwind discuss follow pt
out-performance investor like anticip least point
upsid quarter upsid help de-risk top end
organ guidanc comp becom challeng
set acceler thesi discuss
model acceler build throughout
new product launch contribut growth easier
comp deliveri drive organ growth segment
pt overal growth
million except ep
sever headwind oper margin remain
comfort margin guidanc impli
bp expans includ bp headwind brevi cyclo fx impli
bp underli improv specif guidanc impli margin
manag discuss variou headwind discuss
base ep impact quantifi call math impli bp margin
headwind factor describ note pt differenti full year
margin abnorm low baxter compar prior year margin
bp higher bp lower full year margin
respect model high end impli guidanc line
consensu remain comfort magnitud headwind ultim driven
brevi cyclo revenu degrad may potenti off-set upsid
certain segment deliveri nutrit
deliveri key stabilizationsuppli dynam primari issu
drive baxter organ growth deliveri last year deliveri
guidanc encourag came surpris mani howev intra-quart
recaptur leav us confid model line segment guidanc addit
note momentum stabil alon add pt growth given easier comp
organ growth med deliveri add pt baxter overal organ growth
lead acceler discuss baxter abil deliv
organ growth set top-line growth driven moder
headwind pipelin launch pharma pump emerg market dynam
remain underappreci investor like drive multipl higher outlin
dynam acceler detail
result schedul april post-clos confer call april
million except ep
see risk guidanc quarter though paclitaxel risk
well understood see paclitaxel risk like impact use
materi bd expos coverag
take risk-adjust approach guidanc quarter
given lack visibl dcb adcom june
lower estim peripher model
model bd intervent growth versu
guidanc drive annual underli top-line
growth estim lower end
guidanc rang updat dcb assumpt
modest chang fx drive drive ep estim
compani guidanc rang
see risk guidanc updat
quarter
broad fundament look solid though dcb guidanc like
overshadow quarter top-line estim
ep estim line consensu
see estim achiev model underli
growth line guidanc reflect momentum
stabil manag indic quarter top-line growth
would bp midpoint annual
guidanc rang driven anniversari strong flu season
bp pull-through pharm system order bp
anniversari difficult comp surgeri relat back
order follow hurrican last year bp per ceo
confer call seri see broad fundament solid
even lower guidanc like acceler requir
perform meet expect increas investor confid
back half year
beyond quarter dcb updat june key catalyst pertain
paclitaxel debat continu remain dubiou mortal signal see
look forward addit commentari bd call expect
issu resolv fda panel expect june
result announc schedul may pre-market confer call
guidanc underli sale growth adj ep guidanc
million except ep
comfort street estim model organ
growth bp momentum deceler low end
guidanc rang line lower
estim bp account eluvia urolog
disrupt discuss continu believ
pocket upsid model may abl off-set
headwind model reflect bp momentum
deceler cardiolog stabil stabil
medsurg comfort updat estim account
potenti disrupt softer eluvia sale given fda
warn letter paclitaxel note impact
eluvia impli bp headwind growth model
bp deceler pi bp
deceler ic
guid sustain expect manag
chang organ guidanc remain comfort
midpoint guid though risk adjust
estim bp account eluvia urolog
disrupt refer previous expect
eluvia sale vs broad rang bp growth
lower estim bp account impact urolog
boston disclos suppli chain disrupt steril urolog lower
estim bp account impact remain multipl driver
upsid model off-set eluvia/urolog includ augmenix exalt structur
heart model current assum upsid exalt backhalf manag
guid structur heart sale model assum
see path sale driven increment lotu
watchman collect impli addit bp growth note lotu
launch europ late march expect us launch earli boston
first player singl use duodenoscop market seen
increas regulatori scrutini fda given infect risk exalt may
financi driver
earn risk organ growth acceler greater focu
remain comfort high end earn rang vs
vs slightli ep estim driven
bp margin expans bp high end bp rang
driven analysi recent margin contribut see
result announc schedul april pre-market call et
busi momentum point materi upsid versu street
estim manag preliminari guidanc
repres y/i growth manag point
revenu fall first quarter model
sale y/i growth bp
street model assum pt momentum
deceler us model y/i growth pt
deceler ex us model y/i growth impli
pt deceler saw continu expect
volume-driven growth outpac price headwind possibl
could see beat momentum stabil impli
upsid versu estim would expect rais
guidanc least beat said expect trade
dynam volatil evidenc under-perform
cover earn note investor remain cautiou given
loom libr approv would expect profit take post
quarter libr receiv fda approv prior
libr risk expect icgm label becom clear
gen libr real time alarm alert like
approv via icgm channel could come mid-year
said libr launch necessarili mean acut
headwind new patient add given continu expand
penetr limit volum driven benefit
pharmaci channel given limit awar suggest pharmaci driven
price headwind come dme patient switch channel libr via
icgm could sentiment risk threat price tier pharmaci
bia continu posit long term pathway sale growth
becom clear driven on-going roll-out ii increas access
shift pharmaci channel iii launch profession cgm devic iv
on-going integr via icgm pathway multipl pump compani trial
non-intens market unit health recent approv fulli
dispos vi launch vii smart pen integr
busi momentum like continu driver off-set fade hardwar
revenu disrupt pharmaci channel shift libr next gener
result schedul may after-market confer call et
million except ep
fda approv
expect seem reason model sale
slightli street close high end
guidanc guidanc estim impli
organ growth pt momentum deceler
achiev model tavr growth pt momentum
deceler impli q/q growth
q/q growth prior two year critic growth
impli pt deceler surgic sale impli
pt deceler manag commentari point
softer growth improv cours year
model reflect room upsid see
path top end rang
tavr guidanc de-risk manag guid tavr
growth analyst day decemb
expect rais guidanc like derisk given
boston commentari control lotu launch settlement
boston tavr suit avoid uk germani injunct
posit low-risk data physician dilig suggest
immedi notic inflect adopt rel
intermedi risk expect see benefit low-risk
tavr estim see creep back half ahead
mitral upcom catalyst edward guid mitral sale model
pascal sale cardioband pascal ce mark came earlier
expect quarter see suggest upsid estim compani
see posit rule mitraclip-pasc litig look updat follow
preliminari injunct hear april see
result announc april after-market confer call pm et
million except ep
see upsid us base busi number globu us
spine franchis continu demonstr strength grow
market abil take share bp annual
averag past year sale guidanc like
emb mid upper singl digit growth us spine consist
model organ growth us spine pt
momentum deceler may prove
conserv given expect stabil spine ii competit
rep hire iii valu implant pull-through discuss
note even pt deceler would
line stack comp would
revenu upsid overal globu
robot swing factor driver sentiment
discuss excelsiusgp placement clear focu area
investor given innov trend
importantli long-term pull valu
manag note begin show believ
street model low-to-mid teen placement vs
mse look sever piec commentari call includ
backlog trend quarterli cadenc albeit volatil ii competit dynam
mazor integr stealth iii pull-through
trauma contribut build throughout year late involv seri
invest key hire ramp product support compani
anticip trauma launch admittedli got slower start manag
set expect gradual launch build throughout year expect
back half weight launch progress pull seen
continu robot placement manag commentari suggest comfort
consensu model contribut model low
end contribut bp globu growth
million except ep
top-line estim line consensu
top-line estim line consensu reflect
organ growth includ growth bioscienc
lowest growth model year easiest
comp bioscienc discuss follow result
taken conserv approach estim assum
renew process certain licens china continu
impact sale partial quarter expect bioscienc
ramp throughout year remind similar event relat
china licens happen year ago grifol bioscienc
busi acceler later quarter grifol
underli bioscienc busi strong last
sever quarter end market demand protein remain
healthi believ continu
center addit impact gross
margin like see continu pressur inorgan center
addit mix weak albumin given china licens
issu expect factor improv back
half along collect cost volum scale model sequenti
improv throughout quarterli gross margin level model
oper margin bp y/i bp q/q driven
variou dynam combin haema biotest shanghai raa center
agreement lead greater minor interest could influenc quarterli
result ep quarter line consensu note gross
margin estim pt street
expect addit ambar updat quarter detail like come
june grifol present addit ambar result late march secondari endpoint
discuss follow data present last octob yet convinc
therapi given trial fail primari endpoint disclosur late march limit
